CN101535280B - 芳基磺酰胺化合物 - Google Patents

芳基磺酰胺化合物 Download PDF

Info

Publication number
CN101535280B
CN101535280B CN2007800426055A CN200780042605A CN101535280B CN 101535280 B CN101535280 B CN 101535280B CN 2007800426055 A CN2007800426055 A CN 2007800426055A CN 200780042605 A CN200780042605 A CN 200780042605A CN 101535280 B CN101535280 B CN 101535280B
Authority
CN
China
Prior art keywords
solution
compound
mmol
alkyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800426055A
Other languages
English (en)
Chinese (zh)
Other versions
CN101535280A (zh
Inventor
乔纳森·B·贝尔
纪劳姆·L·莱塞尼
布拉德·E·斯利布斯
韦恩·J·费尔布罗瑟
约翰·A·弗莱加尔
迈克尔·F·T·凯勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inst Medical W & E Hall
Genentech Inc
Original Assignee
Inst Medical W & E Hall
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Medical W & E Hall, Genentech Inc filed Critical Inst Medical W & E Hall
Publication of CN101535280A publication Critical patent/CN101535280A/zh
Application granted granted Critical
Publication of CN101535280B publication Critical patent/CN101535280B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN2007800426055A 2006-11-15 2007-11-15 芳基磺酰胺化合物 Active CN101535280B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85931506P 2006-11-15 2006-11-15
US60/859,315 2006-11-15
PCT/US2007/084873 WO2008061208A2 (en) 2006-11-15 2007-11-15 Arylsulfonamide compounds

Publications (2)

Publication Number Publication Date
CN101535280A CN101535280A (zh) 2009-09-16
CN101535280B true CN101535280B (zh) 2012-06-27

Family

ID=39276199

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800426055A Active CN101535280B (zh) 2006-11-15 2007-11-15 芳基磺酰胺化合物

Country Status (9)

Country Link
US (1) US8168645B2 (enExample)
EP (1) EP2094672B1 (enExample)
JP (1) JP5366817B2 (enExample)
CN (1) CN101535280B (enExample)
AU (1) AU2007319209B2 (enExample)
CA (1) CA2666837C (enExample)
ES (1) ES2423029T3 (enExample)
NZ (1) NZ577442A (enExample)
WO (1) WO2008061208A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009085216A2 (en) 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
US8071766B2 (en) 2008-02-01 2011-12-06 Takeda Pharmaceutical Company Limited HSP90 inhibitors
AU2009249106A1 (en) * 2008-05-21 2009-11-26 Genentech, Inc. Arylsulfonamide compounds, compositions and methods of use
US8168784B2 (en) * 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
MX2012003007A (es) * 2009-09-10 2012-04-11 Novartis Ag Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer.
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
WO2013090645A1 (en) 2011-12-13 2013-06-20 Buck Institute For Research On Aging Methods for improving medical therapies
BR112014015322A8 (pt) 2011-12-23 2017-06-13 Novartis Ag compostos e composições para inibir a interação de bcl2 com parceiros de ligação
CN104125955A (zh) 2011-12-23 2014-10-29 诺华股份有限公司 用于抑制bcl2与结合配偶体相互作用的化合物
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
EP3099380B1 (en) 2014-01-28 2021-08-11 Buck Institute for Research on Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
CA3087262A1 (en) 2018-01-10 2019-07-18 Recurium Ip Holdings, Llc Benzamide compounds
CN108276395B (zh) * 2018-02-09 2021-02-26 合肥华方医药科技有限公司 一种多沙唑嗪杂质的制备方法
CN108570039B (zh) * 2018-04-25 2022-09-23 上海美迪西生物医药股份有限公司 一类具有抑制抗凋亡蛋白活性的化合物及其制备和应用
CN109851535A (zh) * 2019-01-30 2019-06-07 天津现代职业技术学院 一种制备4-氟-3-(三氟甲磺酰基)苯磺酰胺的方法
CN113248415B (zh) * 2021-05-26 2022-08-09 苏州正永生物医药有限公司 一种abt-737关键中间体的制备方法以及abt-737的制备方法
PT4426434T (pt) 2021-11-02 2025-11-24 Flare Therapeutics Inc Agonistas inversos de pparg e suas utilizações

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
ATE372330T1 (de) 2002-03-21 2007-09-15 Abbott Lab N-sulfonylurea-apoptosis-förderer
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8614318B2 (en) * 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7642260B2 (en) * 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
DE602004025494D1 (de) 2003-11-20 2010-03-25 Mitsubishi Gas Chemical Co Flüssiges cyclohexantricarbonsäureanhydrid
JP5284641B2 (ja) * 2004-05-26 2013-09-11 アボット・ラボラトリーズ Ｎ−スルホニルカルボキシイミドアミドアポトーシス促進剤
CA2577752A1 (en) * 2004-08-20 2006-03-02 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
US20070072870A2 (en) * 2004-12-08 2007-03-29 Solvay Pharmeceuticals B.V. Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
PT1888550E (pt) * 2005-05-12 2014-09-03 Abbvie Bahamas Ltd Promotores de apoptose

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Andrew M. Petros, et al..Discovery of a Potent Inhibitor of the Antiapoptotic Protein Bcl-xL from NMR and Parallel Synthesis.《J. Med. Chem.》.2005,第49卷(第2期),第656-663页. *
Suzanne Cory, et al..Killing cancer cells by flipping the Bcl-2/Bax switch.《CANCER CELL》.2005,第5-6页. *

Also Published As

Publication number Publication date
WO2008061208A2 (en) 2008-05-22
CA2666837A1 (en) 2008-05-22
HK1134283A1 (en) 2010-04-23
AU2007319209A1 (en) 2008-05-22
CA2666837C (en) 2015-01-13
US20100056517A1 (en) 2010-03-04
ES2423029T3 (es) 2013-09-17
EP2094672B1 (en) 2013-05-29
AU2007319209B2 (en) 2012-04-19
US8168645B2 (en) 2012-05-01
NZ577442A (en) 2012-02-24
EP2094672A2 (en) 2009-09-02
JP5366817B2 (ja) 2013-12-11
JP2010510237A (ja) 2010-04-02
WO2008061208A3 (en) 2008-07-03
CN101535280A (zh) 2009-09-16

Similar Documents

Publication Publication Date Title
CN101535280B (zh) 芳基磺酰胺化合物
KR101886459B1 (ko) S-나이트로소글루타티온 리덕타제 억제제로서의 신규한 치환된 퀴놀린 화합물
JP6059228B2 (ja) ユビキチン特異的プロテアーゼ７の選択的かつ可逆的な阻害剤
ES2914099T3 (es) Inhibidores novedosos de ULK1 y métodos de uso de los mismos
CN108834412B (zh) 嘧啶及其变体、及其用途
CN101143845B (zh) 取代喹啉甲酰胍衍生物、其制备方法及其医药用途
CN101641339A (zh) 用于预防和治疗心血管疾病的化合物
JP5990187B2 (ja) Ｓ−ニトロソグルタチオン還元酵素阻害薬としての新規な置換二環芳香族化合物
WO2016022460A1 (en) Potent dual brd4-kinase inhibitors as cancer therapeutics
WO2018145621A1 (zh) 喹啉类化合物、其制备方法及其医药用途
AU2019218187B2 (en) Dioxinoquinoline compounds, preparation method and uses thereof
TW200916458A (en) Heterocyclic compounds and methods of use thereof
MX2007002433A (es) Derivados de quinazolinona y su uso como inhibidores de b-raf.
US20150158815A1 (en) Novel phenyl-pyridine/pyrazine amides for the treatment of cancer
CN102341374A (zh) 作为kcnq2/3调节剂的取代的3-氨基-2-巯基喹啉类
CN106478606A (zh) N‑取代吲哚类衍生物及其应用
JP5227179B2 (ja) ３，６−ジヒドロ−２−オキソ−６ｈ−１，３，４−チアジアジン誘導体
CN105585565A (zh) 含2-苯胺基-4-噻唑基吡啶衍生物及其制法和药物组合物与用途
CN111440177B (zh) 一种取代吡唑并[1,5-a]嘧啶类化合物及其制备方法和应用
ES2328929T3 (es) Dihidroquinazolinas 2-sustituidas.
WO2025073221A1 (zh) 苯胺基嘧啶并杂环类化合物及其制备方法、药物组合物和应用
CN116348114B (zh) 硫代苯并咪唑衍生物或其药学上可接受的盐及其用途
HK1134283B (en) Arylsulfonamide compounds
CN113620873B (zh) 含锌结合基以及喹啉骨架的化合物的制备方法和用途
CN116143700A (zh) 酞嗪酮类化合物及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant